[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"figo-grade-2-endometrial-endometrioid-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:figo-grade-2-endometrial-endometrioid-adenocarcinoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100569108","outcomes-of-low-risk-endometrial-cancer-with-isolated-tumor-cells-in-the-sentinel-lymph-nodes-a-prospective-multicenter-single-arm-observational-study-100569108",false,"NCT06689956","Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study","Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective Multicenter Single-Arm Observational Study","Inclusion Criteria:\n\n* Low-risk endometrial cancer, defined as endometrioid, grade 1 or 2, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA (FIGO 2023 stages IA1 and IA2), without substantial\u002Fextensive LVSI (≥ 5 vessels involved) at final pathology. Patients with focal LVSI (\\\u003C 5 vessels involved) will be included.\n\n  * Complete surgical staging, including pelvic sentinel lymph node (SLN) biopsy per National Comprehensive Cancer Network (NCCN) guidelines and ultrastaging.\n  * Extent of disease in SLN: ITC (defined as tumor cell aggregates ≤ 0.2 mm or \\\u003C 200 cells)\n  * No adjuvant treatment after surgery\n  * Research consent provided.\n\nExclusion Criteria:\n\n* Prior neoadjuvant chemotherapy.\n\n  * Planning to receive adjuvant treatment.\n  * Presence of synchronous cancer (excluding non-melanoma skin cancer).\n  * Extent of disease in SLN: micrometastasis (\\> 0.2 to ≤ 2.0 mm) or macrometastasis (\\> 2.0 mm).\n  * Presence of substantial\u002Fextensive LVSI (≥ 5 vessels involved) at final pathology.\n  * Prior invasive cancer diagnosis within 5 years of study entry (excluding non-melanoma skin cancer).","ALL",{"count":18,"type":19},212,"ESTIMATED","OBSERVATIONAL","This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.",[23,24,25,26],"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","Stage IA1 Endometrial Cancer FIGO 2023","Stage IA2 Endometrial Cancer FIGO 2023","RECRUITING","2026-02-17",{"date":30,"type":31},"2026-02-19","ACTUAL",{"date":33,"type":31},"2024-12-04",{"date":35,"type":19},"2029-10-31",{"name":37,"class":38},"Mayo Clinic","OTHER",20]